CoChat

Glucagon‐like peptide‐1(GLP‐1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Open access
Luo, Guojing, Liu, Hong, Lu, Hongyun · 2016 · British Journal of Clinical Pharmacology
Cited by 67

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

This review summarizes current knowledge about glucagon‐like peptide 1 receptor agonists (GLP‐1 RA) and their effects on bone metabolism and fracture risk. Recent in vivo and in vitro experiments indicated that GLP‐1 RA could improve bone metabolism. GLP‐1 could affect the fat‐bone axis by promoting osteogenic differentiation and inhibiting adipogenic differentiation of bone mesenchymal precursor cells (BMSCs), which express the GLP‐1 receptor. GLP‐1 RA may also influence the balance between osteoclasts and osteoblasts, thus leading to more bone formation and less bone resorption. Wnt/β‐catenin signalling is involved in this process. Mature osteocytes, which also express the GLP‐1 receptor, produce sclerostin which inhibits Wnt/β‐catenin signalling by binding to low density lipoprotein receptor‐related protein (LRP) 5 and preventing the binding of Wnt. GLP‐1 RA also decreases the expression of sclerostin (SOST) and circulating levels of SOST. In addition, GLP‐1 receptors are expressed in thyroid C cells, where GLP‐1 induces calcitonin release and thus indirectly inhibits bone resorption. Furthermore, GLP‐1 RA influences the osteoprotegerin(OPG)/receptor activator of nuclear factor‐κB ligand (RANKL)/receptor activator of nuclear factor‐κB (RANK) system by increasing OPG gene expression, and thus reverses the decreased bone mass in rats models. However, a recent meta‐analysis and a cohort study did not show a significant relationship between GLP‐RA use and fracture risk. Future clinical trials will be necessary to investigate thoroughly the relationship between GLP‐1 RA use and fracture risk in diabetic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.12777

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 67

Metadata

Authors
Luo, G., Liu, H., & Lu, H.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2015-11-06
Volume
81
Issue
1
Pages
78-88
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2117779964
Cited by
67
References
23
FWCI
4.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.